THE FRENCH PARADOX: HOW CAN WE EXPLAIN THE ASSIMILATION OF HEALTH BIOTECHNOGIES?
Bertrand Pauget () and
Additional contact information
Bertrand Pauget: European Business School, Paris, France
Xavier Parisot: European Business School, Paris, France
Scientific Bulletin - Economic Sciences, 2013, vol. 12, issue 2, 85-94
There is in France and more generally in Europe a paradox. In the agro industry business, the use of biotechnology is suspicious and controversy (see for example the emblematic case of GMOs), the subject is little debate in the health sector. Yet, in those two sectors, the production process of biotechnology is the same. How can we explain those differences? This article aims to explain the reasons for the acceptance of biotechnology in the business of health. Health professionals interviewed in this study leave use the biotechnology as a tool to improve their practices and benefiting their patients. In doing so, they play a key role to facilitate their consumption by the public. This article is based on a qualitative and exploratory methodology. Our sample consists of leaders of biotech companies or selling biotechnology and doctors who use them.
Keywords: biotechnology; acceptance; technological assimilation; identity. (search for similar items in EconPapers)
JEL-codes: L20 I19 (search for similar items in EconPapers)
References: View complete reference list from CitEc
Citations Track citations by RSS feed
Downloads: (external link)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:pts:journl:y:2013:i:2:p:85-94
Access Statistics for this article
Scientific Bulletin - Economic Sciences is currently edited by Logica Banica
More articles in Scientific Bulletin - Economic Sciences from University of Pitesti Contact information at EDIRC.
Series data maintained by Logica Banica ().